^
    HLA-DRB1*01:01
    Multiple Myeloma
    bortezomib
    Sensitive: C3 – Early Trials
    Cancer Sci - 1 week
    HLA-DQB1*05:01
    Multiple Myeloma
    bortezomib
    Sensitive: C3 – Early Trials
    Cancer Sci - 1 week
    HLA-DQB1*03:02
    Multiple Myeloma
    bortezomib
    Sensitive: C3 – Early Trials
    Cancer Sci - 1 week
    No biomarker
    Multiple Myeloma
    pomalidomide + elotuzumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    carfilzomib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib + panobinostat
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib + pegylated liposomal doxorubicin
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    SVd
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    thalidomide
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    isatuximab-irfc
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    prednisone + thalidomide + melphalan
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    lenalidomide + daratumumab/hyaluronidase
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    lenalidomide + elotuzumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    lenalidomide + daratumumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    selinexor
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    lenalidomide + ixazomib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    daratumumab/hyaluronidase
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    bortezomib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    lenalidomide
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    VTD
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    belantamab mafodotin
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    denosumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    melphalan flufenamide
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide + isatuximab-irfc
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    lenalidomide + carfilzomib
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    daratumumab + pomalidomide
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    daratumumab
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    isatuximab-irfc
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    idecabtagene vicleucel
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    zoledronic acid
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    daratumumab + thalidomide
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    thalidomide + daratumumab/hyaluronidase
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    pomalidomide + daratumumab/hyaluronidase
    Sensitive: A1 - Approval
    No biomarker
    Multiple Myeloma
    dexamethasone tablets
    Sensitive: A1 - Approval
    Chr t(11;14)
    Multiple Myeloma
    venetoclax
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    lenalidomide + bortezomib
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    bortezomib + elotuzumab
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    D-VTd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    ixazomib
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    bortezomib
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    RD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    VMP
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    VRD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    bendamustine
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    melphalan
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    venetoclax + dexamethasone
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    cyclophosphamide oral
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    carfilzomib + panobinostat
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    panobinostat
    Sensitive: A2 - Guideline
    Chr del(17)(p13)
    Multiple Myeloma
    bortezomib
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    carfilzomib + pomalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    PVD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    EloRd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    IRd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    KRd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    DRd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    DVMP
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    CyBorD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    EloPd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    Isa-PD
    Sensitive: A2 - Guideline
    Chr t(11;14)
    Multiple Myeloma
    VenVd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    DVD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    IsaKd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    DKd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    DCEP
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    selinexor + pomalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    selinexor + daratumumab
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    BVD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    BRD
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    ixazomib + pomalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    pomalidomide
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    lenalidomide + panobinostat
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    D-KRd
    Sensitive: A2 - Guideline
    No biomarker
    Multiple Myeloma
    galinpepimut-S
    Sensitive: B - Late Trials
    No biomarker
    Multiple Myeloma
    LCAR-B38M
    Sensitive: B - Late Trials
    Chr amplification(1q)
    Multiple Myeloma
    VRD
    Resistant: B - Late Trials
    Chr t(11;14)
    Multiple Myeloma
    venetoclax + bortezomib
    Sensitive: B - Late Trials
    Chr del(17p)
    Multiple Myeloma
    bortezomib + selinexor
    Sensitive: B - Late Trials
    No biomarker
    Multiple Myeloma
    KD
    Sensitive: B - Late Trials
    No biomarker
    Multiple Myeloma
    VD
    Sensitive: B - Late Trials
    Chr del(17p)
    Multiple Myeloma
    DVD
    Sensitive: B - Late Trials
    Chr t(14;16)
    Multiple Myeloma
    DVD
    Sensitive: B - Late Trials
    Chr t(4;14)
    Multiple Myeloma
    DVD
    Sensitive: B - Late Trials
    Chr del(17p)
    Multiple Myeloma
    lenalidomide + elotuzumab
    Sensitive: B - Late Trials
    CD38 expression
    Multiple Myeloma
    daratumumab
    Sensitive: B - Late Trials
    No biomarker
    Multiple Myeloma
    venetoclax + bortezomib + dexamethasone
    Sensitive: B - Late Trials
    Chr del(17p)
    Multiple Myeloma
    daratumumab
    Sensitive: B - Late Trials
    Chr t(14;16)
    Multiple Myeloma
    daratumumab
    Sensitive: B - Late Trials
    Chr t(4;14)
    Multiple Myeloma
    daratumumab
    Sensitive: B - Late Trials
    BCL2 overexpression
    Multiple Myeloma
    venetoclax
    Sensitive: B - Late Trials
    No biomarker
    Multiple Myeloma
    PBCAR269A
    Sensitive: B - Late Trials
    TNFRSF17 expression
    Multiple Myeloma
    belantamab mafodotin
    Sensitive: B - Late Trials
    RPL5 expression
    Multiple Myeloma
    bortezomib
    Sensitive: B - Late Trials